Unity Biotechnology Inc (UBX) gains 1.01% for July 21

Equities Staff  |

Unity Biotechnology Inc (NASDAQ: UBX) shares gained 1.01%, or $0.04 per share, to close Wednesday at $3.99. After opening the day at $3.95, shares of Unitynology fluctuated between $4.02 and $3.89. 286,370 shares traded hands a decrease from their 30 day average of 725,942. Wednesday's activity brought Unitynology’s market cap to $218,872,248.

Unitynology is headquartered in Brisbane, California, and employs more than 70 people.

About Unity Biotechnology Inc

UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY's current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases.

Visit Unity Biotechnology Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Unity Biotechnology Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Unity Biotechnology Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content